Physician profile
Robert John Branton
NPI 1851388144
$2,054.78
in general payments reported to CMS, 2019-2025
26 companies · $15.85 in 2025
The $15.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $101 · 2021: $457 · 2022: $408 · 2023: $491 · 2024: $412 · 2025: $15.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.31 | 2021-2024 | Qulipta, Ubrelvy, Viberzi |
| Amgen INC. | $220.76 | 2019-2022 | |
| Lilly USA, LLC | $163.16 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $143.73 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $111.96 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $96.61 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $61.24 | 2019-2021 | |
| Novo Nordisk INC | $50.37 | 2019-2024 | Wegovy, Saxenda |
| Merck Sharp & Dohme LLC | $42.41 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $38.77 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.26 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $31.61 | 2019 | |
| Currax Pharmaceuticals LLC | $29.85 | 2022-2023 | Contrave, Nexlizet, Nexletol |
| Vbi Vaccine (Delaware) INC. | $29.42 | 2023 | Prehevbrio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.91 | 2024 | |
| Abbott Laboratories | $24.62 | 2021-2022 | |
| Corcept Therapeutics | $23.93 | 2021 | |
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.45 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $19.01 | 2023 | Arexvy, Shingrix |
| Allergan, INC. | $18.16 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.02 | 2024 | Givlaari |
| Medtronic, INC. | $17.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.88 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Branton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.